Stephanie J. Lee, MD, MPH
When I was a volunteer at Fred Hutchinson Cancer Research Center — before I went to medical school — I met a pair of siblings who helped me decide to go into stem cell transplantation. A girl had donated her bone marrow to her older brother. And while the transplant had cured his leukemia, it was now attacking his body, the result of a condition called graft-versus-host disease (GVHD). At the time, there was little that could be done to stop it, and it was just so horribly sad. I kept thinking that this shouldn’t happen; a cure shouldn’t make people so sick. That boy’s experience has never been far from my mind. Today, I lead a national research network that seeks to better understand GVHD and create more effective therapies for it.
One of the best parts of my job is participating in team science, working with colleagues here and from all over the world, to improve the lives of stem cell transplant recipients. This is not a competitive atmosphere; rather, we support and push each other to do better. I’m really fortunate to be part of such a collaborative environment. I’m also thankful that I can divide my time between doing research and seeing patients. The relationships I’ve forged with patients and their family members over the years have been a very meaningful part of my life.
Specialty: Medical Oncology
I specialize in providing blood and bone marrow transplants for patients with leukemia, myelodysplastic syndromes and other diseases of the blood, bone marrow and lymph nodes. At the Fred Hutchinson Cancer Research Center, I serve as the research director of the Long-Term Follow-Up Program, which provides monitoring and care for patients who have had stem cell transplants.
Through research, I focus on improving transplant outcomes, supporting survivorship and mitigating the impact of chronic GVHD, a life-threatening condition that affects approximately four in 10 transplant recipients. My research has been instrumental in identifying genetic criteria that can better match donors with patients who need transplants, lowering their risk of developing complications like GVHD. In 2018, I was honored to receive the David and Patricia Giuliani/Oliver Press Endowed Chair in Cancer Research. In addition to patient care and research, I am also active in leadership, serving as president-elect of the American Society of Hematology.
SCCA is proud that our own Stephanie Lee, MD, MPH served as the 2020 president of the American Society of Hematology (ASH). Dr. Lee is a highly regarded expert in graft-versus-host disease, as well as blood and bone marrow diseases. We asked Dr. Lee about her time as president of ASH and what she sees as the direction of oncology care in the future.
We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.
Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.
SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.
Key research spans CAR T-cell therapies and treatments for myeloma, leukemia and more.
SCCA's Stephanie J. Lee, MD, MPH, was interviewed by OncLive about the results of the REACH3 trial for chronic GVHD.
Your care team
SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.